Cogent Biosciences (COGT) Operating Leases (2019 - 2026)

Cogent Biosciences (COGT) has 8 years of Operating Leases data on file, last reported at $14.1 million in Q1 2026.

• On a quarterly basis, Operating Leases fell 8.93% year-over-year to $14.1 million in Q1 2026; TTM through Mar 2026 was $14.1 million, a 8.93% decrease from a year earlier, with the FY2025 full-year figure at $14.4 million, down 9.73% from the prior year.
• Operating Leases for Q1 2026 stood at $14.1 million, down from $14.4 million in the prior quarter.
• Over the last five years, Operating Leases for COGT reached as high as $19.0 million in Q2 2022 and fell as low as $1.1 million in Q1 2022.
• Historically, Operating Leases has averaged $15.8 million across 5 years, with a median of $16.7 million in 2024.
• On a YoY basis, Operating Leases climbed as much as 2093.26% in 2022 and fell as far as 56.74% in 2022.
• Year by year, Operating Leases stood at $18.2 million in 2022, then declined by 4.16% to $17.5 million in 2023, then slipped by 8.96% to $15.9 million in 2024, then decreased by 9.73% to $14.4 million in 2025, then slipped by 1.8% to $14.1 million in 2026.
• Per Business Quant data, the three most recent Operating Leases figures were $14.1 million in Q1 2026, $14.4 million in Q4 2025, and $14.6 million in Q3 2025.